Cargando…

Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer

Detalles Bibliográficos
Autores principales:	Curti, Brendan D, Akporiaye, Emmanuel, Sutcliffe, Kim, Bahjat, Keith S, Koguchi, Yoshinobu, Cramer, Julie, Urba, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645162/ http://dx.doi.org/10.1186/2051-1426-3-S2-P148

Ejemplares similares

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer
por: Puri, Sachin, et al.
Publicado: (2014)

A scalable platform for clinical immunophenotyping: assay design and quality control for high complexity flow cytometry
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogs
por: Guerrouahen, Bella S., et al.
Publicado: (2016)

Comparison of proteomic and genomic analyses of vaccine cell lines shows men receiving prostate gvax immunotherapy develop increased humoral responses to common cell line proteins relative to mutated proteins
por: Hulett, Tyler, et al.
Publicado: (2014)

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC
por: Sanborn, Rachel, et al.
Publicado: (2015)

Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas
por: Crittenden, Marka, et al.
Publicado: (2015)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
por: Mougdil, Tarsem, et al.
Publicado: (2015)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies
por: Moudgil, Tarsem, et al.
Publicado: (2014)

Novel strategy to monitor apparent tumor-specific T cells in patients with cancer
por: van de Ven, Rieneke, et al.
Publicado: (2013)

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
por: Andtbacka, Robert HI, et al.
Publicado: (2015)

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
por: Urba, Walter, et al.
Publicado: (2015)

STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors
por: Akporiaye, Emmanuel T, et al.
Publicado: (2013)

Improved efficacy of radiation in combination with TGFβ inhibition in a colorectal cancer mouse model
por: Young, Kristina H, et al.
Publicado: (2013)

Alpha phase modulates the effectiveness and directionality of cortical communication
por: Quax, Silvan C, et al.
Publicado: (2015)

DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9
por: Hilton, Traci L, et al.
Publicado: (2013)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Profiling of suppressive immune subsets in metastasis negative and positive sentinel lymph nodes from patients with HER2- breast cancer
por: van de Ven, Rieneke, et al.
Publicado: (2014)

A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
por: Nayak, Asha, et al.
Publicado: (2014)

Phase I study of combination therapy with weekly paclitaxel and cyclophosphatamide for advanced or recurrent breast cancer
por: Nakayama, T, et al.
Publicado: (2009)

Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma
por: Uhde, Lauren, et al.
Publicado: (2015)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC
por: Hilton, Traci, et al.
Publicado: (2014)

γδ T cell activation may contribute to antitumor immunity stimulated by intralesional BCG immune therapy for cutaneous melanoma metastases
por: Ramos, Romela, et al.
Publicado: (2015)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients
por: Snook, Adam, et al.
Publicado: (2015)

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study
por: Naing, Aung, et al.
Publicado: (2015)

Identification of protein kinase G I alpha interacting proteins as potential targets to prevent cardiac remodeling
por: Blanton, Robert, et al.
Publicado: (2013)

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Burris, Howard, et al.
Publicado: (2013)

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Ansell, Stephen, et al.
Publicado: (2013)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib
por: Telang, Sucheta, et al.
Publicado: (2014)

Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer
por: Shehata, M, et al.
Publicado: (2010)

Intratumoral injection of STING ligand promotes abscopal effect
por: Baird, Jason R, et al.
Publicado: (2014)

Preliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients
por: Berry, John S, et al.
Publicado: (2013)

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v4089npi4r7c5gtnu47dot6sm5